KRAS and non-small cell lung carcinoma: Among patients in the PS 0–1 cohort, the median rwToT was 7.6 months for those with KRAS-positive NSCLC and 7.0 months for those with KRAS wild-type NSCLC, both resembling that of the full PS 0–1 cohort with nonsquamous NSCLC (median 7.6 months).